Composition and method for promoting intestinal barrier healing
AssigneeGlycom A/S
InventorsLouise Kristine Vigsnæs, Bruce McConnell, Sami Damak, Francis Foata, Norbert Sprenger
Life of this patent
Estimating the term…
Abstract
A composition and associated packs and methods for (i) promoting gastrointestinal barrier healing in the upper intestinal tract and/or small intestine of a non-infant human suffering from chronic intestinal barrier inflammation, and/or (ii) maintaining remission in the upper intestinal tract and small intestine of a non-infant human suffering from chronic intestinal barrier inflammation. The composition contains an effective amount of a combination of 6′-sialyllactose (6′-SL) and lacto-N-tetraose (LNT).
Claims21
1-21 (canceled)
A method comprising
- selecting a non-infant human experiencing oesophageal inflammation;
- selecting an initial dosage of a composition comprising an effective amount of one or two synthetic human milk oligosaccharides (HMOs) chosen from the group consisting of 6′-sialyllactose (6′-SL), lacto-N-tetraose (LNT) and a mixture thereof, the selected amount effective to induce direct activation of G protein-coupled receptor 35 (GPR35) in the oesophagus of the non-infant human;
- and
- promoting GPR35 mediated mucosal healing in the oesophagus of the non-infant human experiencing the oesophageal inflammation by administering the initial dosage of the composition during an initial treatment phase.
A method comprising:
- selecting a non-infant human experiencing inflammation in the small intestine associated with Crohn's disease;
- selecting an initial dosage of a composition comprising an effective amount of one or two synthetic human milk oligosaccharides (HMOs) chosen from the group consisting of 6′-sialyllactose (6′-SL), lacto-N-tetraose (LNT) and a mixture thereof, the selected amount effective to induce direct activation of G protein-coupled receptor 35 (GPR35) in the small intestine of the non-infant human;
- and
- promoting GPR35 mediated mucosal healing in the small intestine of the non-infant human by administering the initial dosage of the composition during an initial treatment phase.
A method comprising:
- selecting a non-infant human experiencing inflammation in the small intestine associated with coeliac disease;
- selecting an initial dosage of a composition comprising an effective amount of one or two synthetic human milk oligosaccharides (HMOs) chosen from the group consisting of 6′-sialyllactose (6′-SL), lacto-N-tetraose (LNT) and a mixture thereof, the selected amount effective to induce direct activation of G protein-coupled receptor 35 (GPR35) in the upper GI tract or the small intestine of the non-infant human;
- and
- promoting GPR35 mediated mucosal healing in the upper GI tract or the small intestine of the non-infant human by administering the initial dosage of the composition during an initial treatment phase.
Dependencies are inferred from the claim text.